GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Unilever

Glaxo (GSK) rejects an offer from Unilever to acquire its consumer business worth 50 billion pounds ($68 billion). However, Unilever is likely to pursue the acquisition of the business.

Glaxo (GSK) Rejects Unilever's $68B Bid for Consumer Business

Unilever faces a dilemma after its 50 billion pound ($68 billion) offer for GlaxoSmithKline's consumer healthcare assets was rejected -- should it raise the bid and risk overpaying or seek another route to expand in healthcare?

Unilever's offer for GSK's consumer health raises doubts, questions over strategy

The British consumer goods giant has confirmed it has made an offer and is still interested in buying the consumer food healthcare division of GSK co-owned by Pfizer

Unilever's Bid for Glaxo's Consumer Assets - The Deal That No One Likes

Has there ever been a time in the last 50 years when investors and Unilever PLC (LSE:ULVR) management alike were not concerned about sluggish growth? With brands such as (deep breath) Hellmann's, Vaseline, Ben & Jerry's, Knorr, Magnum, Wall's, Cif, Domestos, Dove, Lifebuoy, Lux, Omo and Sunsilk, the company specialises in everyday products – and if you don't think Ben & Jerry's is an everyday product then you should meet my wife.

Unilever yet to demonstrate it would be the right owner of GSK's Consumer Healthcare division

Shares of GlaxoSmithKline surged on Monday, while Unilever stock tumbled following a failed $68 billion bid by the latter to acquire the pharmaceutical giant's consumer healthcare arm.

Europe Markets: GlaxoSmithKline shares soar after Unilever bids for its consumer healthcare unit

GlaxoSmithKline PLC (LSE:GSK) said the £50bn offer by Unilever PLC (LSE:ULVR) for its Consumer Healthcare business fundamentally undervalues the business. Unilever made three unsolicited approaches to acquire the business – in which GlaxoSmithKline (GSK) has a 68% stake (the rest is owned by US drugs giant Pfizer Inc (NYSE:PFE)) – and all were rejected by GSK.

GlaxoSmithKline shares rise after it rejects Unilever bid for its consumer healthcare division

(Reuters) -Dove soap maker Unilever signalled on Monday it would pursue a deal for GlaxoSmithKline's consumer health business, calling it a "strong strategic fit" after its 50-billion-pound approach ($68.4 billion) was rejected.

Unilever says GSK consumer arm 'strong strategic fit' for business

GlaxoSmithKline and Pfizer will hold out for a better bid of at least £60 billion for their joint consumer healthcare venture, in opposition to an earlier offer they didn't like, Financial Times writes. They're rejecting a £50 billion offer from Unilever, which GSK said was “fundamentally undervalued.

GlaxoSmithKline, Unilever Spar Over Future of GSK's Consumer Health Business

Unilever Plc has held talks with banks about additional financing for a potential sweetened offer for GlaxoSmithKline Plc's consumer products division, Bloomberg reported on Sunday, citing people familiar with the matter.

Unilever to weigh raising offer for Glaxo Consumer unit - Bloomberg

GlaxoSmithKline rejects three purchase offers from Unilever for its Consumer Healthcare business. The U.K. pharma giant says the business is well-positioned to sustainably grow ahead of its categories in the years to come.

GSK Spurns $68.4B Bid From Unilever For Its Consumer Healthcare Business, Opts to Spin-off The Unit

Glaxo says Unilever has made three proposals to buy the GSK Consumer Healthcare business. Its most recent approach in December was for 50 billion pounds ($68.4 billion).

GlaxoSmithKline Rejects Unilever Offer for its Consumer Health Unit

Consumer goods giant Unilever has approached GlaxoSmithKline about buying the pharmaceutical group's consumer goods arm, after a newspaper reported that a 50 billion-pound ($68.4 billion) bid it made had been rebuffed.

Factbox-GSK's consumer health business

Consumer goods giant Unilever has made a bid for pharmaceutical group Glaxosmithkline's consumer goods business worth roughly 50 billion pounds ($68.4 billion), Britain's Sunday Times reported.

Unilever offers 50 billion pounds for GSK unit -report

Eli Lilly

An expert panel at the World Health Organization (WHO) recommended the use of treatments developed by Eli Lilly And Co (NYSE: LLY) and GlaxoSmithKline Plc (NYSE: GSK) / Vir Biotechnology Inc (NASDAQ: VIR) for COVID-19 patients. In its guidelines published in the British  Medical Journal , the panel has recommended Lilly's baricitinib (Olumiant), a Janus kinase (JAK) inhibitor, combined with corticosteroids for severe COVID-19 patients.

WHO Recommends Glaxo, Eli Lilly Drugs For COVID-19 Treatment Amid Omicron Surge

Vir Biotechnology

Glaxo (GSK) and Vir are looking to get authorization for the intramuscular administration of their COVID-19 drug candidate, sotrovimab, which is currently authorized for intravenous administration.

Glaxo (GSK), Vir Seek EUA for Intramuscular Sotrovimab in US

Shares of Vir Biotechnology Inc. VIR, -1.60% were up 1.0% in trading on Thursday after the company and GlaxoSmithKline GSK, -0.01% formally asked the Food and Drug Administration to update the authorization for their COVID-19 treatment to include intramuscular administration. GSK's stock was up 0.1% after the news was announced.

Vir, GSK ask FDA to update EUA for their monoclonal antibody to include intramuscular administration

The U.S. government enters into an agreement with Glaxo (GSK) and Vir Biotechnology (VIR) to procure an additional 600,000 doses of sotrovimab for early treatment of COVID-19.

Glaxo (GSK) & Vir to Supply More COVID Antibody Doses in US

GlaxoSmithKline (GSK) closed at $45.04 in the latest trading session, marking a +0.45% move from the prior day.

GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know

GlaxoSmithKline plc's (GSK) CEO Emma Walmsley Presents at JPMorgan 40th Annual Healthcare Conference (Transcript)

GlaxoSmithKline PLC ( GSK , Financial) is ready for a “landmark year,” CEO Emma Walmsley said at Tuesday's session of the 40th Annual JP Morgan Health Care Conference.

Glaxo CEO: 2022 Will be 'Landmark' Year for Company

The U.S. has agreed to buy 600,000 more doses of GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc's (NASDAQ: VIR) COVID-19 antibody therapy for an undisclosed sum. The companies would supply the additional doses of sotrovimab to the U.S. in Q1 of 2022, taking the tally of doses secured by nations worldwide to roughly 1.7 million.

US To Purchase 600K Additional Doses of GSK-Vir's COVID-19 Antibody Therapy

GlaxoSmithKline GSK, -0.60% GSK, +0.83% and partner Vir Biotechnology VIR, +1.96% said Tuesday that the U.S. government will buy 600,000 doses of sotrovimab, an investigational monoclonal antibody for early COVID-19 treatment. The extra doses will be delivered in the first quarter of 2022 to the U.S., which has an option to purchase more in the second quarter.

GlaxoSmithKline, Vir shares up as U.S. orders more doses of COVID treatment sotrovimab

The new deal brings to 1 million the total number of doses of the therapy that the U.S. government has purchased, according to GlaxoSmithKline.

Glaxo and Vir Sell 600,000 Covid Antibody Doses to U.S.

GlaxoSmithKline GSK, +2.26% GSK, +1.24% and partner Vir Biotechnology VIR, -0.62% said Tuesday that the U.S. government will buy 600,000 doses of sotrovimab, an investigational monoclonal antibody for early COVID-19 treatment. The extra doses will be delivered in the first quarter of 2022 to the U.S., which has an option to purchase more in the second quarter.

GlaxoSmithKline to ship 600,000 more doses of COVID treatment sotrovimab to U.S.

908 Devices

BOSTON--(BUSINESS WIRE)--908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, today announced that GlaxoSmithKline (NYSE: GSK) has purchased an additional REBEL™ cell culture media analyzer. GSK will now have a total of five REBEL analyzers being used by its biologics and vaccine process development teams. “We are pleased that GSK has once again chosen our REBEL desktop device as part of its process development efforts to br

News for GlaxoSmithKline Stock (GSK)